Matthew J. Barth MD
Matthew J. Barth
MD
Clinical Associate Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Pediatric Hematology-Oncology; Pediatrics
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDProfessional Summary:
I am a pediatric hematologist/oncologist. I see young patients who are admitted to the John R. Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center.
In addition to my clinical practice, I have a keen interest in hematological malignancies and the use of targeted therapies in their treatment. As a fellow in the lymphoma translational research laboratory at RPCI, I began investigating novel therapeutic anti-CD20 antibodies in cell-line and xenograft models of rituximab resistant B-cell non-Hodgkin lymphoma (B-NHL). Based on my initial findings with the antibody ofatumumab, the University at Buffalo granted me the Dr. Henry C. and Bertha H. Buswell Fellowship, an award for promising physician-scientists who are in the beginning stages of their careers. The award allowed me to continue my work with this novel monoclonal antibody and begin exploring why B-cell lymphoma cells become resistant to multiple therapeutic modalities, including anti-CD20 immunotherapy and traditional cytotoxic chemotherapy. For children with relapsed/refractory disease, this resistance portends a survival rate that is less than 20 percent.
Using cell-line models of resistant disease and a variety of techniques such as gene expression profiling, phosphoproteomics, phospho-flow cytometry and western blotting, I have sought to characterize aberrant signal transduction pathway activation in the setting of resistant B-NHL and the ability to target relevant pathways as a means to overcome or bypass therapeutic resistance. These efforts have led to collaborative research with several investigators throughout the country who have similar interests, e.g., the clinical investigation of the anti-CD20 monoclonal antibody rituximab in childhood B-NHL.
In addition to my basic science and translational research, I am involved in developing trials that investigate other novel therapies in the setting of relapsed/refractory disease. I am co-PI of an investigator-initiated trial studying the anti-CD20 monoclonal antibody obinutuzumab, in combination with chemotherapy, for relapsed/refractory childhood B-NHL. I am also an industry-sponsored investigator researching the role of rituximab in the treatment of de novo childhood mature B-NHL.
I often supervise residents on their research projects and periodically welcome medical students, college students and high school students to work with me in the lab—mostly as part of the RPCI summer research program.
I teach medical students, residents and fellows rotating through pediatric hematology and oncology, in outpatient clinics and at the bedside on inpatient units. Using brief impromptu lectures/discussions, I also teach these trainees about disease processes they encounter as they rotate through hematology/oncology. I also lecture the pediatric residents during the hematology/oncology portion of their didactic series. Additionally, I teach our hematology/oncology fellows, in small-group didactic lectures and in both inpatient and outpatient clinical encounters.
Education and Training:
- Fellowship, Pediatric Hematology/Oncology, University at Buffalo (2011)
- Residency, Pediatrics, University at Buffalo (2008)
- Internship, Pediatrics, University at Buffalo (2006)
- MD, Medicine, SUNY Upstate Medical University (2005)
- BA, Chemistry, Stonehill College, Cum Laude (1999)
- BS, Biology, Stonehill College, Cum Laude (1999)
Employment:
- Clinical Associate Professor, Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences (2022-present)
- Assistant Professor, Pediatric Oncology, Roswell Park Comprehensive Cancer Center (2011-present)
- Attending Physician, Hematology/Oncology, Oishei Children's Hospital (2011-present)
- Attending Physician, Hematology/Oncology, Roswell Park Comprehensive Cancer Center (2011-present)
- Assistant Professor, Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2014–2022)
- Research Assistant Professor, Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2011–2014)
- Research Assistant, Upstate Medical University College of Medicine (2002)
- Technical Research Assistant, Channing Laboratory, Brigham and Women‘s Hospital (1999–2001)
- Research Associate, Stonehill College (1998)
- Research Assistant, Stonehill College (1997–1998)
Awards and Honors:
- 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma: Best Poster Abstract (2018)
- Hem Onc Today: Next Generation Innovator (2017)
- International Society of Paediatric Oncology: Young Investigator Award (2016)
- 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma: Outstanding Translational Biology Research (2015)
- University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Henry C. and Bertha H. Buswell Fellowship (2011)
- 11th International Conference on Malignant Lymphoma: Travel Award (2011)
- Roswell Park Cancer Institute: Best Basic Science Fellow Research Report (2011)
- University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Thomas F. Frawley, MD Residency Research Fellowship (2011)
- National Institutes of Health: Loan Repayment Program Award (2012-2017)
- Buffalo Spree Magazine: Top Doctors in Western New York (2020-2022)
Research Expertise:
- Hematological malignancies
- Non-Hodgkin lymphoma
- Pediatric lymphoma
Grants and Sponsored Research:
- December 2020–November 2023
Development of Pediatric Patient Derived Tumor Models
Roswell Park Alliance Foundation
Role: Principal Investigator - November 2019–November 2021
Roswell Park Pediatric Precision Medicine/Developmental Therapeutics Scholar Program
Hyundai Hope on Wheels
Role: Co-Principal Investigator - December 2019–May 2021
Adoptive Cellular Therapy for Relapsed/Refractory Pediatric Solid Tumors
Hyundai Hope on Wheels
Role: Principal Investigator - May 2019–April 2020
Targeting Oncogenic MicroRNAs in MYC Associated Aggressive B Cell Non-Hodgkin Lymphoma
Roswell Park Alliance Foundation
Role: Principal Investigator
$70,000 - July 2013–June 2018
Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL
St. Baldricks Foundation
Role: Principal Investigator
$560,000 - July 2015–June 2016
Targeted Therapy in Resistant B-NHL
National Cancer Institute
Role: Principal Investigator - September 2012–December 2015
Targeted Therapeutic Approaches to Overcoming Resistance in Pediatric Aggressive B-NHL
Hyundai Hope on Wheels
Role: Principal Investigator
$250,000 - November 2014–October 2015
Targeting CD30 Using Brentuximab Vedotin (SGN-35), an Anti-CD30 Antibody Drug Conjugate, in Non-Hodgkin Lymphoma
Wildermuth Foundation
Role: Principal Investigator
$35,000 - November 2013–October 2015
Preclinical and Translational Investigation of Ibrutinib (PCI-32765) in Childhood, Adolescent and Young Adult B-Cell Non-Hodgkin Lymphoma
Janssen Pharmaceuticals
Role: Co-Investigator
$30,000 - July 2014–June 2015
Targeted Therapies in B-NHL
National Cancer Institute
Role: Principal Investigator - July 2012–June 2014
Novel Therapeutic Approaches in the Treatment of B-Cell Lymphoma
National Cancer Institute
Role: Principal Investigator - July 2011–June 2014
Biological Activity of Lenalidomide and Ofatumumab in B-cell Lymphoma
University at Buffalo: Henry C. and Bertha H. Buswell Research Fellowship
Role: Principal Investigator
$240,000 - February 2012–December 2013
Biological Activity of Histone Deacetylase Inhibitors in the Treatment of Pediatric Lymphoma
Roswell Park Alliance Foundation
Role: Principal Investigator
$40,000
Journal Articles:
- Parisi R, Patel RR, Rood G, Bowden A, Turco G, Korones DN, Andolina JR, Comito M, Barth M, Weintraub L. (2023) Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients. Pediatric blood & cancer (Mar), 70(3): e30139.
- Barth M, Xavier AC, Armenian S, Audino AN, Blazin L, Bloom D, Chung J, Davies K, Ding H, Ford JB, Galardy PJ, Hanna R, Hayashi R, Lee-Miller C, Machnitz AJ, Maloney KW, Marks L, Martin PL, McCall D, Pacheco M, Reilly AF, Roshal M, Song S, Weinstein J, Zarnegar-Lumley S, McMillian N, Schonfeld R, Sundar H. (2022) Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN (Nov), 20(11): 1267-1275.
- Guney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak KT, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen AW, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. (2022) A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances (May)
- Andolina JR, Fries C, Boulware R, Vargas A, Fraint E, Barth M, Abrusko S, Comito M, Monteleone P. (2022) Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants. Journal of pediatric hematology/oncology (Jan)
- Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. (2021) A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia (Oct), 35(10): 2994-2997.
- Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. (2021) Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer discovery (Jun), 11(6): 1424-1439. doi:10.1158/2159-8290.CD-20-0564
- Craig E, Wiltsie LM, Beaupin LK, Baig A, Kozielski R, Rothstein DH, Li V, Twist CJ, Barth M. (2021) Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review. Journal of pediatric surgery (Feb).
- Chu Y, Nayyar G, Kham Su N, Rosenblum JM, Soon-Shiong P, Lee J, Safrit JT, Barth M, Lee D, Cairo MS. (2020) Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. Journal for immunotherapy of cancer (Oct), 8(2). doi:10.1136/jitc-2020-001238
- Harker-Murray PD, Pommert L, Barth MJ. (2020) Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN (Aug), 18(8): 1125-1134.
- Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass DA. (2020) Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN (Aug), 18(8): 1105-1123.
- Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez-Ilizaliturri FJ. (2020) Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma. EJHaem (Jul), 1(1): 122-132. doi:10.1002/jha2.2
- Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth MJ, Hernandez-Ilizaliturri FJ. (2020) Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. eJHaem (Apr).
- Torka P, Barth MJ, Ferdman R, Hernandez-Ilizaliturri FJ. (2019) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. Curr Hematol Malig Rep (Oct), 14(5): 426-438.
- Barth MJ, Minard-Colin V. (2019) Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol (Jun), 185(6): 1111-1124.
- Runckel K, Barth MJ, Mavis C, Gu JJ, Hernandez-Ilizaliturri FJ. (2018) The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv (Dec), 2(23): 3516-3525.
- Chu Y, Lee S, Shah T, Yin C, Barth MJ, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. (2018) Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. OncoImmunology (Oct).
- Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. (2018) Excellent outcomes in children and adolescents with CNS burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol (Aug).
- Bhatti M, Ippolito T, Mavis C, Gu J, Cairo MS, Lim MS, Hernandez-Ilizaliturri FJ, Barth MJ. (2018) Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget (Apr), 9(31): 21820-21830.
- Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP. (2017) Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol (Dec), 179(5): 739-747.
- Awasthi A, Rolland DCM, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. (2017) A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget (Dec), 8(69): 113895-113909. doi:10.18632/oncotarget.23040
- Gu JJ, Singh A, Xue E, Mavis C, Barth MJ, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ. (2017) Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget (Dec), 9(3): 4020-4033.
- Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, Bolaender A, Erdjument-Bromage H, Sadek J, Chadburn A, Barth MJ, Dela Cruz FS, Rainey A, Kung AL, Chiosis G, Cesarman E. (2017) Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther (Sep), 16(9): 1779-1790.
- Chu Y, Yahr A, Huang B, Ayello J, Barth MJ, Cairo MS. (2017) Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology (Jun), 6(9).
- Beaupin LM, Bostrom B, Barth MJ, Franklin I, Jaeger R, Kamath P, Schreiber B, Bleyer A. (2017) Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review. Leuk Lymphoma (Apr), 58(4): 766-772.
- Barth MJ, Chu Y, Hanley PJ, Cairo MS. (2016) Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol (May), 173(4): 597-616.
- Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2016) Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood (Mar), 127(9): 1128-1137.
- Alrazzak M, Beaupin LM, Kinyon P, Barth MJ. (2016) The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience. J Pediatr Hematol Oncol (Jan), 38(1): e16-e20.
- Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. (2015) Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma and precursor B-acute lymphoblastic leukaemia. Br J Haematol (Dec), 171(5): 763-775.
- Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. (2015) Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clin Cancer Res (Oct), 21(19): 4391-4397.
- Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. (2015) Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children‘s Oncology Group Pilot Study Report. Br J Haematol (Aug), 170(3): 367-371.
- Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. (2015) Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol (May), 169(4): 506-519.
- Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth MJ, Czuczman MS, Cairo MS. (2015) Targeting CD20 Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunol Res (Apr), 3(4): 333-344.
- Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth MJ, Cairo MS. (2014) Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol (Nov), 167(3): 394-401.
- Barth MJ, Czuczman MS. (2013) Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol (Dec), 9(12): 1829-1839.
- Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. (2013) Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol (Sep), 162(5): 678-683.
- Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth MJ, Zhi J, Cairo MS. (2013) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children‘s Oncology Group report. Leukemia (Apr), 27(5): 1174-1177.
- Barth MJ, Raetz E, Cairo MS. (2012) The future role of monoclonal antibody therapy in childhood acute leukaemias. Br J Haematol (Oct), 159(1): 3-17.
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. (2012) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol (Feb), 156(4): 490-498.
- DeMeo DL, Lange C, Silverman EK, Senter JM, Drazen JM, Barth MJ, Laird N, Weiss ST. (2002) Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. Genet Epidemiol (Nov), 23(4): 335-348.
- Silverman EK, Palmer LJ, Mosley JD, Barth MJ, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE, Weiss ST. (2002) Genome-wide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet (May), 70(5): 1229-1239.
- Silverman EK, Mosley JD, Palmer LJ, Barth MJ, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE, Weiss ST. (2002) Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet (Mar), 11(6): 623-632.
- Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. (1900) Ibrutinib significantly inhibited Bruton. Oncoimmunology (Jan), 8(1): e1512455. doi:10.1080/2162402X.2018.1512455
Books and Book Chapters:
- Barth MJ, Goldman S. (2019) In: “Resistance to Monoclonal Antibody Therapeutics in Lymphoma”. Springer
- Barth MJ, Hochberg J, El-Mallawany NK, Cairo MS. (2017) In: "Monoclonal Antibodies Targeting Hematological Malignancies".
Abstracts:
- Rodney RM, Rodic V, Barth MJ, Cairo MS, Hermiston ML. (2016) Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells. Blood, (Dec) 2944-2944
- Tiwari A, Rolland D, Elmacken M, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson K, Lim MS, Cairo MS. (2015) Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab Against RTX Sensitive/Resistant Burkitt Lymphoma: Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity. Blood, (Dec) 1550-1550
- Bhatti M, Ippolito T, Mavis C, Barth MJ. (2015) PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma. Blood, (Dec) 1558-1558
- Awasthi A, Ayello J, van de Ven C, Elmacken M, Reggio C, Barth MJ, Cairo MS. (2014) Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL. Blood, (Dec) 2251-2251
- Frys S, Czuczman NM, Mavis C, Rolland DCM, Lim MS, Tiwari A, Cairo MS, Miles RR, Barth MJ. (2014) Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models. Blood, (Dec) 1769-1769
- Awasthi A, Rolland DCM, Elmacken M, Reggio C, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. (2014) A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins. Blood, (Dec) 5481-5481
- Alrazzak M, Bambach BJ, Rokitka DA, Barth MJ. (2014) Hyperammonemic Encephalopathy Secondary to Pegylated Asparaginase Treated with Oral Lactulose Solution and Intravenous Sodium Benzoate/Sodium Phenylacetate. Pediatr Blood Cancer, (May) S48-S48
- Chu Y, Yahr A, Ayello J, van de Ven C, Barth MJ, Czuczman MS, Cairo MS. (2014) Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) Regression and Improve Survival in Human BL Xenografted NSG Mice. Blood, (Feb) S257-S257
- Barth MJ, Mavis C, Czuczman NM, Frys S, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2013) MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo. Blood, (Dec) 647-647
- Lee S, Yin C, Ayello J, O'Connell T, van de Ven C, Muniz M, Barth MJ, Cairo MS. (2013) Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis. Blood, (Dec) 2503-2503
- Awasthi A, Rolland D, Barth MJ, Ayello J, van de Ven C, Czuczman MS, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. (2013) Global Phosphoproteomics Analysis Of Burkitt Lymphoma (BL) Demonstrates Abnormal Protein Phosphorylation In BCR, Spliceosome, mTOR and Chemokine Signaling Pathways In Rituximab Induced Resistant BL. Blood, (Dec) 928-928
- Pais F, Barth MJ, Miles RR, Hermiston ML. (2013) Histone Deacetylase Inhibitors Enhance Cell Death in Burkitt Lymphoma Cells by Modulating Expression of the WNT/. Blood, (Dec) 1291-1291
- Frys S, Skomra A, Czuczman NM, Mavis C, Rolland D, Lim M, Tiwari A, Cairo MS, Czuczman MS, Hernandez-Ilizaliturri FJ, Barth MJ. (2013) The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. Blood, (Dec) 5144-5144
- Pais F, Lee S, Rodic V, Barth MJ, Cairo MS, Hermiston M, Miles RR. (2013) Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood, (Dec) 243-243
- Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. (2013) Rituximab Pharmacokinetics in Children and Adolescents with De Novo Intermediate and Advanced Mature B-Cell Lymphoma/Leukaemia: A Children’s Oncology Group (COG) Report. J Clin Oncol, (May) 3055-3055
- Barth MJ, Goldman S, Zhi J, Smith L, Harrison L, Perkins SL, Shiramizu B, Gross T, Sanger W, Cairo MS. (2012) Safety and Pharmacokinetics of Rituximab in Combination with FAB Chemotherapy in Children and Adolescents with Stage III/IV Mature B-NHL and B-cell Leukemia +/- CNS Disease: A Children’s Oncology Group Report. Br J Haematol, (Nov)
- Goldman S, Hochberg J, Harrison L, Kallis M, Barth MJ, Galardy P, Miles R, Sanger W, Shiramizu B, Lim M, Perkins SL, Hermiston M, Frazer JK, Cairo MS. (2012) Reduced Burden of Oncologic Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20 Mature B-Cell Lymphoma. Br J Haematol, (Nov)
- Czuczman NM, Barth MJ, Dawar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. Blood, (Nov) 2761-2761
- Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models. Blood, (Nov) 2756-2756
- Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Shiramizu B, Sanger W, Barth MJ, Cairo MS. (2012) Outcome of Advanced Stage (III/IV) Intermediate-Risk Patients with Mature B-NHL Using Rituximab Plus FAB Group B4 Chemotherapy: A Children’s Oncology Group Report. Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin’s Lymp. Br J Haematol, (Nov)
- Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL). Blood, (Nov) 3717-3717
- Awasthi A, Ayello J, van de Ven C, Glassman D, Sabulski A, Barth MJ, Cairo MS. (2012) Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20+ sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL). Blood, (Nov) 4865-4865
- Awasthi A, Ayello J, van de Ven C, Glassman D, Sabulski A, Barth MJ, Cairo MS. (2012) Obinutuzumab (GA101): Exhibits Enhanced Cell Death and ADCC Compared to Rituximab in RTX Resistant and Sensitive Cell Lines Against B-Cell Non-Hodgkins Lymphoma. Br J Haematol, (Nov)
- Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood, (Nov) 2757-2757
- Frys S, Barth MJ, Gu J, Mavis C, Gibbs JF, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors. Blood, (Nov) 1649-1649
- Dawar R, Barth MJ, Mavis C, Skitzki J, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. (2012) Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models. J Clin Oncol, (May)
- Barth MJ, Pendurti G, Mavis C, Czuczman NM, Gibbs JF, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. (2011) Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples. Blood, (Nov) 4972-4972
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. Blood, (Nov)
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. Blood, (Nov) 3917-3917
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma. J Clin Oncol, (May) 8095-8095
Professional Memberships:
- Pediatric Transplant and Cellular Therapy Consortium (2022–present)
- International Society of Paediatric Oncology (2016–2019)
- Children's Oncology Group (2011–present)
- American Society of Pediatric Hematology/Oncology (2011–2018)
- American Society of Clinical Oncology (2011–2017)
- American Society of Hematology (2011–present)
Presentations:
- "PI3K Inhibitors in non-Hodgkin Lymphoma" 7th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma (2022)
- "Current State of Biology in B-NHL" Children's Oncology Group Sping Meeting, Non-Hodgkin Lymphoma Committee Meeting (2021)
- "NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomas" Media Interview; Hematology News (2020)
- "Supportive Care in Pediatric Cancer" 2019 Oncology Case Manager and Medical Director Program Webinar; National Comprehensive Cancer Network (2019)
- "2B8T2M, a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Cytotoxicity Against Rituximab Sensitive and Resistant" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "High miR-17-92 Expression is Associated with In Vitro Chemoresistance in Burkitt Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, In-Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Low Cardiac Toxicity Following Immunochemotherapy with Reduced Anthracycline Dosing in Children, Adolescents and Young Adults with B-Cell Non-Hodgkin Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Low Level of Cerebrospinal Fluid (CSF) Rituximab (RTX) Following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with De Novo Mature B-Cell Non-Hodgkin Lymphoma (B-NHL)" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Omipalisib (GSK458), a Dual Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro and In Vivo Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD 20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed /Refractory Mature B-Cell Non-Hodgkin Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Reduced Burden of Oncologic Therapy in Children, Adolescents and Young Adults with Good Risk (GR) CD20+ Mature B-Cell Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Regulation of Cytokine Release and Anti-Tumor Effect of Anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an IL-15 Superagonist" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2018)
- "Chemotherapy and Biologic Agents: Novel Targeted Therapies for Non-Hodgkin's Lymphomas" Annual Meeting; American Society of Hematology; Moderating Session: Lymphoma - Pre-Clinical (2017)
- "Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)" Annual Meeting; American Society of Hematology (2017)
- "Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)" Annual Meeting; American Society of Hematology (2017)
- "Clinical Application of Tumor Genomics in Pediatric Oncology" Pediatric Grand Rounds; University at Buffalo (2017)
- "Intravenous Pegaspargase - Are There More Hypersensitivity Reactions?" 48th Annual Congress; International Society of Paediatric Oncology (2016)
- "Polatuzumab Vedotin (PV, Anti-CD79b-VC-MMAE) Significantly Increased Apoptosis/Reduced Cell Proliferation & Improved Survival Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)" 48th Annual Congress; International Society of Paediatric Oncology (2016)
- "Reduced Burden of Therapy in Intermediate Risk Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial" 48th Congress; International Society of Paediatric Oncology (2016)
- "Childhood Cancer Awareness" Media Interview; WKBW; AM Buffalo (2016)
- "Ways to Improve Treatment for Certain Types of Childhood Cancer" Media Interview; WGRZ; WNY Living (2016)
- "Preliminary Results of a Reduced Burden of Therapy Trial by Incorporation of Rituximab and Intrathecal Liposomal Cytarabine in Children, Adolescents and Young Adults with Intermediate and High Risk Mature B-Cell Lymphoma/Leukemia" Annual Meeting; American Society of Clinical Oncology (2016)
- "Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial in Children, Adolescents and Young Adults with Intermediate and High Risk Aggressive B-Cell Non-Hodgkin Lymphoma" Annual Meeting; American Society of Clinical Oncology (2016)
- "Antibody Drug Conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) Exhibit Enhanced Cell Death Targeted to CD79b+ Burkitt Lymphoma (BL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)" Annual Meeting; American Association for Cancer Research (2016)
- "Obinutuzumab (GA101) versus Rituximab Against Rituximab-Sensitive and -Resistant Burkitt Lymphoma (BL) Differentially Phosphorylate BCR, Fc-Gamma Receptor, and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathways" Annual Meeting; American Association for Cancer Research (2016)
- "Novel Agents for B-Cell Non-Hodgkin Lymphoma" Spring Meeting; Children‘s Oncology Group; Non-Hodgkin Lymphoma Committee (2016)
- "Enhanced In Vitro and In Vivo Targeting of Rituximab Sensitive and Resistant Burkitt Lymphomas (BL) by Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells in Combination with a Histone Deacetylase Inhibitor, Romidepsin" BMT Tandem Meetings; American Society for Blood and Marrow Transplantation (2016)
- "Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer Cells have Significant Cytotoxicity Against Poor Risk CD20+ Burkitt Lymphoma In Vitro and in Xenografted NSG Mice" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Ibrutinib Alone and in Combination with Dexamethasone Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May Be a Potential Targeted Agent in Combination Therapy in Patients with PMBL" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Ibrutinib Significantly Improves Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Incorporating Mitochondrial DNA (MTDNA) Measurement to Supplement Minimal Residual Disease (MRD) Assessment in B-NHL/Leukemia Treatment Strategies" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "MK-2206, an Akt Inhibitor, Decreases Proliferation, Induces Cell Cycle Arrest and Increases Responsiveness to Chemotherapy in Therapy-Sensitive and –Resistant Burkitt Lymphoma Cell Line Models" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Obinutuzumab vs. Rituximab (RTX) Differentially Phosphorylate BCR, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins in RTX Sensitive/Resistant Burkitt Lymphoma (BL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Obinutuzumab vs. Rituximab Significantly Enhances Apoptosis, ADCC In-Vitro and Overall Survival In-Vivo of Rituximab Sensitive/Resistant Burkitt Lymphoma (BL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Rituximab and Second Generation Monoclonal Antibodies" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Safety and Efficacy of Intrathecal (IT) Liposomal Cytarabine (L-ARA-C) in Children, Adolescent and Young Adult (CAYA) Patients with De Novo Mature B-NHL/Leukemia (MBLL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Pediatric Cancer Research Foundation (2015)
- "Targeting the PI3K/Akt/Mtor Pathway Improves Chemoresponsiveness in Cell Line Models of Chemotherapy Sensitive and Resistant Burkitt Lymphoma" 47th Congress; International Society of Paediatric Oncology (2015)
- "Obinutuzumab Compared to Rituximab Significantly Enhances Cell Death, Antibody Dependent Cytotoxicity (ADCC) and Improves Overall Survival Against CD20+ Rituximab-Sensitive/-Resistant Burkitt Lymphoma (BL) and Precursor Lymphoblastic Leukemia (Pre-B-ALL)" Annual Meeting; American Association for Cancer Research (2015)
- "Deregulation of the PI3K/Akt Signal Transduction Pathway is Associated With the Development of Chemotherapy Resistance and Can Be Effectively Targeted To Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models" Annual Meeting; American Society of Hematology; Lymphoma Biology (2014)
- "Ibrutinib Significantly Alters Cell Proliferation and Programmed Cell Death in Burkitt Lymphoma (BL) Cell Lines: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL" Annual Meeting; American Society of Hematology; Lymphoma Biology (2014)
- "Ibrutinib, a Selective and Covalent Inhibitor of the Bruton’s Tyrosine Kinase Significantly Inhibits Cell Proliferation and Induces Apoptosis in PMBL Cell Lines: Ibrutinib May Be a Future Targeted Agent in Combination Therapy in Patients with PMBL" Annual Meeting; American Society of Hematology; Lymphoma Biology (2014)
- "Preclinical Activity of Type-II Anti-CD20 Monoclonal Antibody Obinutuzumab (GA101) Compared with Rituximab (RTX) Both in In-Vitro and Xenograft Models Against RTX Sensitive and Resistant Burkitt Lymphoma" Annual Meeting; American Society of Hematology; Lymphoma Biology (2014)
- "Hyperammonemic Encephalopathy Secondary to Pegylated Asparaginase Treated with Oral Lactulose Solution and Intravenous Sodium Benzoate/Sodium Phenylacetate" Annual Meeting; American Society of Pediatric Hematology/Oncology (2014)
- "Obinutuzumab (GA101) Significantly Increases Overall Survival Against CD20+ Rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL" Annual Meeting; American Association for Cancer Research (2014)
- "Exogenous Overexpression of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells to RTX Induced Apoptosis" Annual Meeting; American Society of Hematology (2013)
- "Histone Deacetylase Inhibitors Enhance Cell Death in Burkitt Lymphoma Cells by Modulating Expression of the WNT/Beta-Catenin Pathway and Survivin" Annual Meeting; American Society of Hematology (2013)
- "MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme (NAE), is Active in Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo" Annual Meeting; American Society of Hematology (2013)
- "Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion of MIR17HG in Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity" Annual Meeting; American Society of Hematology (2013)
- "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Pediatric Case Report with Review of the Literature" Annual Meeting; American Society for Clinical Pathology (2013)
- "Rituximab Pharmacokinetics in Children and Adolescents with De Novo Intermediate and Advanced Mature B-Cell Lymphoma/Leukaemia: A Children’s Oncology Group (COG) Report" Annual Meeting; American Society of Clinical Oncology (2013)
- "Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors" Annual Meeting; American Society of Hematology (2012)
- "Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma" Annual Meeting; American Society of Hematology (2012)
- "MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL)" Annual Meeting; American Society of Hematology (2012)
- "Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models" Annual Meeting; American Society of Hematology (2012)
- "Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models" Annual Meeting; American Society of Hematology (2012)
- "Obinutuzumab (GA101): Exhibits Enhanced Cell Death and ADCC Compared to Rituximab in RTX Resistant and Sensitive Cell Lines Against B-Cell Non-Hodgkins Lymphoma" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma; Pediatric Cancer Research Foundation (2012)
- "Outcome of Advanced Stage (III/IV) Intermediate-Risk Patients with Mature B-NHL Using Rituximab Plus FAB Group B4 Chemotherapy: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma; Pediatric Cancer Research Foundation (2012)
- "Reduced Burden of Oncologic Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma; Pediatric Cancer Research Foundation (2012)
- "Safety and Pharmacokinetics of Rituximab in Combination with FAB Chemotherapy in Children and Adolescents with Stage III/IV Mature B-NHL and B-cell Leukemia +/- CNS Disease: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma; Pediatric Cancer Research Foundation (2012)
- "Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models" Annual Meeting; American Society of Clinical Oncology (2012)
- "Activity of Rituximab (RIT) and Ofatumumab (OFA) Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines by Complement Dependent Cytotoxicity and Antibody Dependent Cell Mediated Cytotoxicity" Internal Medicine 2012; American College of Physicians Internal Medicine (2012)
- "Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived from Patient Tumor Samples" Annual Meeting; American Society of Hematology (2011)
- "Targeting CD20 in the Treatment of B-Cell Lymphoma: Rituximab and Beyond" Invited Presentation; New York Medical College (2011)
- "Safety and Pharmacokinetics (PK) of Rituximab (R) in Combination with FAB Chemotherapy in Children and Adolescents (C+A) with Stage III/IV Mature B-NHL: A Children‘s Oncology Group Report" 11th International Conference on Malignant Lymphoma; European Society for Medical Oncology/Japanese Society of Medical Oncology (2011)
- "Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines, Rituximab-Resistant Cell Lines, Lymphoma Xenografts" Annual Meeting; American Society of Hematology (2010)
- "Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma" Annual Meeting; American Society of Clinical Oncology (2010)
- "Central Venous Line Related Deep Venous Thrombosis in Pediatric Patients" Pediatric Grand Rounds; University at Buffalo (2009)
- "Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset COPD" International Conference; American Thoracic Society (2002)
- "B2 Adrenergic Receptor Polymorphisms are Not Associated with Rate of Lung Function Decline in a Population-Based Study of Men" International Conference; American Thoracic Society (2001)
- "Family-Based Association Analysis of ARG130GLN IL-13 Polymorphism in the Childhood Asthma Management Program" International Conference; American Thoracic Society (2001)
- "Family-Based Association Analysis of B2AR-16 Polymorphism in the Childhood Asthma Management Program" International Conference; American Thoracic Society (2001)
Service Activities:
- Journal of the NCCN; Issue Editor (2022)
- Abstract Reviewer for 7th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Abstract Reviewer (2022)
- Member, NCCN Sub-Saharan Africa Pediatric B-NHL Guidlines Harmonization Panel; Committee Member (2022–present)
- Scientific Planning Committee, 7th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Scientific Planning Committee (2022)
- National Comprehensive Cancer Network, Pediatric Aggressive Mature B-cell Lymphoma Guideline Panel; Chair (2021–present)
- Drugs of the Future; Peer Reviewer (2021–present)
- Expert Reviews of Anticancer Therapy; Peer Reviewer (2021–present)
- Haematologica; Peer Reviewer (2021–present)
- Frontiers in Genetics; Peer Reviewer (2021–present)
- Journal of the National Comprehensive Cancer Network: Pediatric Burkitt Issue (2020)
- Drugs of Today; Peer Reviewer (2020–present)
- Blood Advances; Peer Reviewer (2020–present)
- Pediatric Investigation; Peer Reviewer (2020–present)
- Pediatric Investigation; Peer Reviewer (2020–present)
- OncoTargets and Therapy; Peer Reviewer (2020–present)
- SurvivorNet, Patient informational video, “Treatment : Treating Non-Hodgkin Lymphoma in Children” (2019)
- National Comprehensive Cancer Network, Pediatric Aggressive Mature B-cell Lymphoma Guideline Panel; Vice-Chair (2019–2021)
- PUNT Pediatric Cancer Collaborative; Board of Directors (2019–present)
- Scientific Reports; Peer Reviewer (2019–present)
- Roswell Park Transfusion Committee (2018–present)
- 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Abstract Reviewer (2018–present)
- Cytometry Part B: Clinical Cytometry; Peer Reviewer (2018–present)
- BMC Hematology; Peer Reviewer (2018–present)
- Clinical Pharmacokinetics; Peer Reviewer (2018–present)
- UBMD Pediatrics: Board of Directors; Secretary (2018–present)
- Pre-clinical-Chemotherapy and Biologic Agents: Novel targeted therapies for non-Hodgkin Lymphomas, American Society of Hematology Annual Meeting; Moderator (2017–present)
- Roswell Park Comprehensive Cancer Center Pediatric Translational Research Group; Co-chair (2017–present)
- The FASEB Journal; Peer Reviewer (2017–present)
- Permanente; Peer Reviewer (2017–present)
- BMC Cancer; Peer Reviewer (2017–present)
- Scientific Review Committee, Roswell Park Cancer Institute (2016–present)
- UB Associates Inc. (2016–2017)
- UBMD Pediatrics: Board of Directors; Member (2016–2017)
- Pediatric Blood and Cancer; Reviewer (2016–present)
- Pediatric Hematology and Oncology; Reviewer (2016–present)
- Faculty Practice Management Plan (2015–2018)
- Journal of Pediatrics; Reviewer (2015–present)
- University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Faculty Council; Member (2014–2018)
- St. Baldrick's Foundation: Research Grant; Grant Reviewer (2014–2015)
- PLOS One; Reviewer (2014–present)
- University at Buffalo: Faculty Senate; Member (2013–2015)
- Women and Children's Hospital of Buffalo Utilization Review Committee (2013)
- Leukemia and Lymphoma; Reviewer (2013–present)
- Children‘s Oncology Group: Non-Hodgkin Lymphoma Committee; Committee Member (2011–present)